Clinical Trials Logo

Disseminated Neuroblastoma clinical trials

View clinical trials related to Disseminated Neuroblastoma.

Filter by:

NCT ID: NCT00408681 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease After Donor Stem Cell Transplant

Start date: June 2006
Phase: N/A
Study type: Interventional

RATIONALE: Lithium carbonate may be an effective treatment for intestinal graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying lithium carbonate in treating patients with acute intestinal graft-versus-host-disease after donor stem cell transplant.

NCT ID: NCT00309907 Completed - Clinical trials for Secondary Acute Myeloid Leukemia

Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant

Start date: April 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well etanercept works in treating young patients with idiopathic pneumonia syndrome after undergoing a donor stem cell transplant. Etanercept may be effective in treating patients with idiopathic pneumonia syndrome after undergoing a donor stem cell transplant.

NCT ID: NCT00093821 Completed - Clinical trials for Recurrent Childhood Acute Lymphoblastic Leukemia

Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors

Start date: September 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of tanespimycin in treating young patients with recurrent or refractory leukemia or selected solid tumors. Drugs used in chemotherapy, such as tanespimycin, work in different ways to stop cancer cells from dividing so they stop growing or die.

NCT ID: NCT00060372 Completed - Clinical trials for Stage IV Breast Cancer

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

Start date: April 2003
Phase: Phase 1
Study type: Interventional

This phase I trial is studying how well ipilimumab works after allogeneic stem cell transplant in treating patients with persistent or progressive cancer. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.

NCT ID: NCT00053950 Terminated - Clinical trials for Recurrent Neuroblastoma

Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma

Start date: December 2002
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of pyrazoloacridine given together with peripheral stem cell or bone marrow transplantation in treating young patients with high-risk neuroblastoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell or bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.

NCT ID: NCT00028522 Completed - Clinical trials for Recurrent Neuroblastoma

R(+)XK469 in Treating Patients With Advanced Neuroblastoma

Start date: December 2001
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of R(+)XK469 in treating patients with advanced neuroblastoma. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die.

NCT ID: NCT00005576 Completed - Clinical trials for Recurrent Neuroblastoma

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

Start date: January 2001
Phase: Phase 1
Study type: Interventional

Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining monoclonal antibody therapy with sargramostim or interleukin-2 may kill more tumor cells. Phase I trial to study the effectiveness of monoclonal antibody therapy given with sargramostim and interleukin-2 in treating children with neuroblastoma who have just completed bone marrow or peripheral stem cell transplantation